Eggehard Josef Holler

List of Publications by Year
in descending order

109 papers	4,566 citations	109321 35 h-index	106344 65 g-index
115 all docs	115 docs citations	115 times ranked	5544 citing authors

#	Article	IF	Citations
1	Novel nanopolymer RNA therapeutics normalize human diabetic corneal wound healing and epithelial stem cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 32, 102332.	3.3	16
2	Multifunctional Nanopolymers for Bloodâ€“Brain Barrier Delivery and Inhibition of Glioblastoma Growth through EGFR/EGFRvIII, c-Myc, and PD-1. Nanomaterials, 2021, 11, 2892.	4.1	9
3	Small-Sized Co-Polymers for Targeted Delivery of Multiple Imaging and Therapeutic Agents. Nanomaterials, 2021, 11, 2996.	4.1	5
4	Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain. Journal of Controlled Release, 2020, 320, 45-62.	9.9	180
5	Single- and Multi-Arm Gadolinium MRI Contrast Agents for Targeted Imaging of Glioblastoma . International Journal of Nanomedicine, 2020, Volume 15, 3057-3070.	6.7	15
6	NIMG-01. MRI VIRTUAL BIOPSY AND TREATMENT OF PRIMARY OR BRAIN METASTATIC TUMORS WITH TARGETED NANOBIOCONJUGATES. Neuro-Oncology, 2020, 22, ii146-ii146.	1.2	0
7	IMMU-50. BBB CROSSING NANO-IMMUNOMEDICINE COMBINATION THERAPY TO TREAT BRAIN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Neuro-Oncology, 2020, 22, ii115-ii115.	1.2	0
8	Bloodâ€“brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nature Communications, 2019, 10, 3850.	12.8	199
9	Polymalic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme. Biomaterials, 2019, 206, 146-159.	11.4	35
10	TMIC-47. INHIBITION OF GLIOBLASTOMA GROWTH THROUGH TUMOR-MICROENVIRONMENT CROSSTALK USING CLINICALLY SUITABLE NANOBIOCONJUGATE. Neuro-Oncology, 2019, 21, vi258-vi258.	1.2	0
11	Blockade of a Laminin-411â€“Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk. Cancer Research, 2019, 79, 1239-1251.	0.9	61
12	A Combination of Tri-Leucine and Angiopep-2 Drives a Polyanionic Polymalic Acid Nanodrug Platform Across the Bloodâ€“Brain Barrier. ACS Nano, 2019, 13, 1253-1271.	14.6	51
13	Abstract 977: Nano immunotherapeutics crossing blood-brain barrier to activate local brain tumor immune system. , 2019, , .		0
14	Abstract 1896: Blockade of laminin-411-notch crosstalk as an effective therapy for glioblastoma treatment. , 2019, , .		0
15	Coarse particulate matter (PM2.5â€“10) in Los Angeles Basin air induces expression of inflammation and cancer biomarkers in rat brains. Scientific Reports, 2018, 8, 5708.	3.3	49
16	Covalent nano delivery systems for selective imaging and treatment of brain tumors. Advanced Drug Delivery Reviews, 2017, 113, 177-200.	13.7	67
17	HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 631-639.	3.3	36
18	Polymalic Acid Tritryptophan Copolymer Interacts with Lipid Membrane Resulting in Membrane Solubilization. Journal of Nanomaterials, 2017, 2017, 1-11.	2.7	5

#	Article	IF	Citations
19	Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. Journal of Controlled Release, 2016, 244, 14-23.	9.9	40
20	Curcumin Targeted, Polymalic Acid-Based MRI Contrast Agent for the Detection of Aβ Plaques in Alzheimer's Disease. Macromolecular Bioscience, 2015, 15, 1212-1217.	4.1	38
21	Quantitative Analysis of PMLA Nanoconjugate Components after Backbone Cleavage. International Journal of Molecular Sciences, 2015, 16, 8607-8620.	4.1	6
22	Multifunctional Self-Assembled Films for Rapid Hemostat and Sustained Anti-infective Delivery. ACS Biomaterials Science and Engineering, 2015, 1, 148-156.	5.2	39
23	MRI Virtual Biopsy and Treatment of Brain Metastatic Tumors with Targeted Nanobioconjugates: Nanoclinic in the Brain. ACS Nano, 2015, 9, 5594-5608.	14.6	78
24	Abstract 3686: Engineering nanoparticles of polymalic acid for controlled delivery of anticancer drugs. , 2015, , .		0
25	Advances in Imaging: Brain Tumors to Alzheimer's Disease. The Bangkok Medical Journal, 2015, 10, 83-97.	0.0	1
26	Ordered and Kinetically Discrete Sequential Protein Release from Biodegradable Thin Films. Angewandte Chemie - International Edition, 2014, 53, 8093-8098.	13.8	27
27	Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?. Journal of Visualized Experiments, 2014, , .	0.3	19
28	Multilayer Films Assembled from Naturally-Derived Materials for Controlled Protein Release. Biomacromolecules, 2014, 15, 2049-2057.	5.4	47
29	Nanoparticles of Esterified Polymalic Acid for Controlled Anticancer Drug Release. Macromolecular Bioscience, 2014, 14, 1325-1336.	4.1	8
30	Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. Journal of Controlled Release, 2013, 171, 322-329.	9.9	42
31	Nanomedicine therapeutic approaches to overcome cancer drug resistance. Advanced Drug Delivery Reviews, 2013, 65, 1866-1879.	13.7	598
32	Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment. Journal of Drug Targeting, 2013, 21, 956-967.	4.4	48
33	Distinct mechanisms of membrane permeation induced by two polymalic acid copolymers. Biomaterials, 2013, 34, 217-225.	11.4	24
34	Abstract 3911: Imaging and treatment of brain metastatic tumors using nanopolymers.. , 2013, , .		0
35	Biocompatible nanopolymers: the next generation of breast cancer treatment?. Nanomedicine, 2012, 7, 1467-1470.	3.3	37
36	The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 291-317.	2.4	610

#	Article	IF	Citations
37	Cellular Delivery of Doxorubicin via pH-Controlled Hydrazone Linkage Using Multifunctional Nano Vehicle Based on Poly(Î²-L-Malic Acid). International Journal of Molecular Sciences, 2012, 13, 11681-11693.	4.1	71
38	Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer. PLoS ONE, 2012, 7, e31070.	2.5	51
39	Modification of Microbial Polymalic Acid With Hydrophobic Amino Acids for Drugâ€Releasing Nanoparticles. Macromolecular Chemistry and Physics, 2012, 213, 1623-1631.	2.2	18
40	New functional degradable and bio-compatible nanoparticles based on poly(malic acid) derivatives for site-specific anti-cancer drug delivery. International Journal of Pharmaceutics, 2012, 423, 84-92.	5.2	62
41	Poly(methyl malate) Nanoparticles: Formation, Degradation, and Encapsulation of Anticancer Drugs. Macromolecular Bioscience, 2011, 11, 1370-1377.	4.1	19
42	The optimization of polymalic acid peptide copolymers for endosomolytic drug delivery. Biomaterials, 2011, 32, 5269-5278.	11.4	54
43	Polymalic Acidâ€"Based Nanobiopolymer Provides Efficient Systemic Breast Cancer Treatment by Inhibiting both HER2/neu Receptor Synthesis and Activity. Cancer Research, 2011, 71, 1454-1464.	0.9	61
44	Abstract 4428: Inhibition of tumor vascular protein laminin-411 by nanobioconjugate for glioma treatment. , 2011, , .		2
45	Abstract 4433: Nanoconjugate mediated inhibition of EGFR expression of triple negative breast cancer. , 2011, , .		0
46	Abstract 3221: Multifunctional nano-bioconjugate based on poly(Î²-L-malic acid) for temozolomide delivery for brain tumor treatment. , 2011, , .		0
47	Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(Î²-L-malic acid). Pharmaceutical Research, 2010, 27, 2317-2329.	3.5	75
48	Nanoconjugate Platforms Development Based in Poly(<mml:math) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 Td (xmlns:mml="http://ww Methyl Esters for Tumor Drug Delivery. Journal of Nanomaterials, 2010, 2010, 1-8.	2.7	19
49	Inhibition of brain tumor growth by intravenous poly(Î²- <scp>l</scp> -malic acid) nanobioconjugate with pH-dependent drug release. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18143-18148.	7.1	156
50	Nanoconjugate based on polymalic acid for tumor targeting. Chemico-Biological Interactions, 2008, 171, 195-203.	4.0	80
51	Physarum polymalic acid hydrolase: Recombinant expression and enzyme activation. Biochemical and Biophysical Research Communications, 2008, 377, 735-740.	2.1	3
52	Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine, 2008, 3, 247-265.	3.3	73
53	Biodegradable Multitargeting Nanoconjugates for Drug Delivery. Fundamental Biomedical Technologies, 2008, , 233-262.	0.2	0
54	Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(Î²-l-malic acid). Journal of Controlled Release, 2007, 122, 356-363.	9.9	69

#	Article	IF	Citations
55	Polycefin, a New Prototype of a Multifunctional Nanoconjugate Based on Poly(Î²-l-malic acid) for Drug Delivery. Bioconjugate Chemistry, 2006, 17, 317-326.	3.6	96
56	Screening for Î²-poly(l-malate) binding proteins by affinity chromatography. Biochemical and Biophysical Research Communications, 2006, 341, 1119-1127.	2.1	8
57	Stage specific expression of poly(malic acid)-affiliated genes in the life cycle of Physarum polycephalum. Spherulin 3b and polymalatase. FEBS Journal, 2006, 273, 1046-1055.	4.7	8
58	High molecular weight methyl ester of microbial poly(Î²,l-malic acid): Synthesis and crystallization. Polymer, 2006, 47, 6501-6508.	3.8	16
59	Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis. Angiogenesis, 2006, 9, 183-191.	7.2	53
60	Use of the giant multinucleate plasmodium of Physarum polycephalum to study RNA interference in the myxomycete. Analytical Biochemistry, 2005, 342, 194-199.	2.4	10
61	Low-Molecular-Weight Poly(Î±-methylÎ²,L-malate) of Microbial Origin: Synthesis and Crystallization. Macromolecular Bioscience, 2005, 5, 172-176.	4.1	8
62	Laminin isoform expression in breast tumors. Breast Cancer Research, 2005, 7, 166-7.	5.0	12
63	Injection of poly(Î²-l-malate) into the plasmodium of Physarum polycephalum shortens the cell cycle and increases the growth rate. FEBS Journal, 2004, 271, 3805-3811.	0.2	12
64	Localization of fluorescence-labeled poly(malic acid) to the nuclei of the plasmodium of Physarum polycephalum. FEBS Journal, 2003, 270, 1536-1542.	0.2	8
65	The DNA-polymerase inhibiting activity of poly(Î²-l-malic acid) in nuclear extract during the cell cycle ofPhysarum polycephalum. FEBS Journal, 2002, 269, 1253-1258.	0.2	7
66	Synthetic substrates and inhibitors of Î²-poly(L-malate)-hydrolase (polymalatase). FEBS Journal, 2000, 267, 5101-5105.	0.2	30
67	ÃŽÂ²-Poly(L-malate) production by non-growing microplasmodia ofPhysarum polycephalum. FEMS Microbiology Letters, 2000, 193, 69-74.	1.8	21
68	Is Î²-poly(L-malate) synthesis catalysed by a combination of Î²-L-malyl-AMP-ligase and Î²-poly(L-malate) polymerase?. FEBS Journal, 1999, 265, 1085-1090.	0.2	23
69	Comparative synthesis and hydrolytic degradation of poly (L-malate) by myxomycetes and fungi. Mycological Research, 1999, 103, 513-520.	2.5	31
70	Multiple polypeptides immunologically related to beta-poly(L-malate) hydrolase (polymalatase) in the plasmodium of the slime mold Physarum polycephalum. FEBS Journal, 1998, 251, 405-412.	0.2	16
71	Helix-Coil Transitions in DNA by Novel Pt(II) Complexes: A pH Melting Study. Journal of Biomolecular Structure and Dynamics, 1998, 15, 1173-1180.	3.5	6
72	Molecular constituents of the replication apparatus in the plasmodium of Physarum polycephalum: identification by photoaffinity labelling. Microbiology (United Kingdom), 1998, 144, 3181-3193.	1.8	23

#	Article	IF	Citations
73	Specificity and Direction of Depolymerization of beta-Poly(L-malate) Catalysed by Polymalatase from Physarum polycephalum. Fluorescence Labeling at the Carboxy-Terminus of beta-Poly(l-malate). FEBS Journal, 1997, 250, 308-314.	0.2	23
74	Helixâ€"Coil Transitions in DNA Using a pH Variation Method: Case of a Melting Paradox as a Function of Ionic Strength. Analytical Biochemistry, 1996, 237, 152-155.	2.4	8
75	DNA polymerase ? of Physarum polycephalum. Current Genetics, 1995, 28, 534-545.	1.7	10
76	Large complexes of .beta.-poly(L-malate) with DNA polymerase .alpha., histones, and other proteins in nuclei of growing plasmodia of Physarum polycephalum. Biochemistry, 1995, 34, 14741-14751.	2.5	25
77	Poly(Î²-<scp>L</scp>-malate) hydrolase from Plasmodia of<i>Physarum polycephalum</i>. Canadian Journal of Microbiology, 1995, 41, 192-199.	1.7	31
78	Monofunctional DNA-platinum(II) adducts block frequently DNA polymerases. Nucleic Acids Research, 1992, 20, 2307-2312.	14.5	10
79	Biological and biosynthetic properties of poly-l-malate. FEMS Microbiology Letters, 1992, 103, 109-118.	1.8	4
80	Specific inhibition of Physarum polycephalum DNA-polymerase-alpha-primase by poly(l-malate) and related polyanions. FEBS Journal, 1992, 206, 1-6.	0.2	25
81	Enhanced levels of cyclic AMP, adenosine(5â€²)tetraphospo(5â€²)adenosine and nucleoside 5â€²-triphosphates in mouse leukemia P388/D1 after treatment with cis-diamminedichloroplatinum(II). Biochemical Pharmacology, 1991, 42, 285-294.	4.4	5
82	Escherichia coli DNA polymerase I: inherent exonuclease activities differentiate between monofunctional and bifunctional adducts of DNA and cis- or trans-diamminedichloroplatinum(II). An exonuclease investigation of the kinetics of the adduct formation. FEBS Journal, 1990, 191, 743-753.	0.2	20
83	The effect of cis-platinum on nucleotide metabolism. Inorganica Chimica Acta, 1989, 159, 121-124.	2.4	4
84	An unusual polyanion from Physarum polycephalum that inhibits homologous DNA-polymerase .alpha. in vitro. Biochemistry, 1989, 28, 5219-5226.	2.5	96
85	Purification and caracterization of DNA polymerase alpha from plasmodia of Physarum polycephalum. FEBS Journal, 1988, 176, 199-206.	0.2	14
86	A DNA polymerase with unusual properties from the slime mold Physarum polycephalum. FEBS Journal, 1987, 163, 397-405.	0.2	14
87	Mode of inhibition of the DNA polymerase of Methanococcus vannielii by aphidicolin. FEBS Journal, 1987, 165, 171-175.	0.2	15
88	In vitro competition between adenosine(5')tetraphospho(5')adenosine and deoxyribonucleic acid in the reaction with diamminedichloroplatinum(II). FEBS Journal, 1986, 161, 621-627.	0.2	10
89	Non-disruptive detection of DNA polymerases in nondenaturing polyacrylamide gels. FEBS Journal, 1985, 151, 311-317.	0.2	20
90	Interaction of DNA polymerase I of Escherichia coli with nucleotides. Antagonistic effects of single-stranded polynucleotide homopolymers. Biochemistry, 1985, 24, 3618-3622.	2.5	15

#	Article	IF	Citations
91	51. Konferenz der Gesellschaft fÃ¼r Biologische Chemie. Metabolism of Diadenosine Tetraphosphate (Ap4A). Held in Regensburg, March 20th and 21st, 1984. Hoppe-Seyler's Zeitschrift FÃ¼r Physiologische Chemie, 1984, 365, 597-612.	1.6	1
92	Noncovalent complexes of diadenosine 5â€²,5â€´-P1,P4-tetraphosphate with divalent metal ions, biogenic amines, proteins and poly(dT). Biochemical and Biophysical Research Communications, 1984, 120, 1037-1043.	2.1	14
93	Circular dichroism and ordered structure of bisnucleoside oligophosphates and their zinc(2+) and magnesium(2+) complexes. Biochemistry, 1983, 22, 4924-4933.	2.5	41
94	Mechanism of Synthesis of Adenosine(5')tetraphospho(5')adenosine (AppppA) by Aminoacyl-tRNA Synthetases. FEBS Journal, 1982, 126, 135-142.	0.2	159
95	Kinetics of anticooperative binding of phenylalanyl-tRNAPhe and tRNAPhe to phenylalanyl-tRNA synthetase of Escherichia coli K10. Biochemistry, 1980, 19, 1397-1402.	2.5	7
96	Labelling of l-Isoleucine tRNA Ligase from Escherichia coli with l-Isoleucyl-bromomethyl Ketone. FEBS Journal, 1976, 63, 419-426.	0.2	24
97	l-Phenylalanine: tRNA Ligase of Escherichia coli K10. The Effect of O S Substitution on Substrate and Ligand Binding Properties of ATP. FEBS Journal, 1976, 67, 171-176.	0.2	8
98	Rapid determination of an amino acid: tRNA ligase Â· aminoacyl adenylate complex on DEAE-cellulose filter disks. Analytical Biochemistry, 1976, 70, 174-180.	2.4	7
99	Quaternary Structure and Catalytic Functioning of l-Phenylalanine: tRNA Ligase of Escherichia coli K10. FEBS Journal, 1975, 56, 605-615.	0.2	13
100	Fluorescence and stopped-flow studies on the N â˘¡ F transition of serumalbumin. Biophysical Chemistry, 1975, 3, 226-233.	2.8	17
101	Productive and unproductive lysozyme-chitosaccharide complexes. Equilibrium measurements. Biochemistry, 1975, 14, 1088-1094.	2.5	38
102	Catalytic mechanism of amino acid:tRNA ligases. Synergism and formation of the ternary enzyme-amino acid-ATP complex. Biochemistry, 1975, 14, 2496-2503.	2.5	35
103	Productive and unproductive lysozyme-chitosaccharide complexes. Kinetic investigations. Biochemistry, 1975, 14, 2377-2385.	2.5	39
104	l-Phenylalanyl-tRNA Synthetase of Escherichia coli K-10. A Reinvestigation of Molecular Weight and Subunit Structure. FEBS Journal, 1974, 43, 601-607.	0.2	71
105	The determination of the dissociation constants of productive and unproductive lysozyme substrate complexes. FEBS Letters, 1974, 40, 25-28.	2.8	5
106	Equilibrium analysis of L-Phe-tRNAPhe complexes with L-phenylalanyl transfer ribonucleic acid synthetase of Escherichia coli K 10. Biochemistry, 1974, 13, 4171-4175.	2.5	23
107	Kinetics of lysozyme-substrate interactions. Biochemical and Biophysical Research Communications, 1970, 40, 166-170.	2.1	21
108	Kinetics of lysozyme-substrate interactions. Biochemical and Biophysical Research Communications, 1969, 37, 423-429.	2.1	29

#	Article	IF	Citations
109	Labelling of the catalytic site of lysozyme. Biochemical and Biophysical Research Communications, 1969, 37, 757-766.	2.1	36